Quantcast

Recent Study Shows Leukothera(TM) Combined with Other Agents Has Enhanced Anti-Leukemia Effects

June 27, 2011

NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ — Recent findings published in the scientific journal Leukemia Research (http://www.sciencedirect.com/science/article/pii/S0145212611002505), showed that when combined with standard anti-leukemia agents, the biological activity of Leukothera(TM), a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects.

The outcome of these in vitro experiments demonstrated that combining Leukothera(TM) with such widely employed drugs as etoposide, mitoxantrone, daunorubicin, busulfan and imatinib killed leukemia cells much more effectively than when the agents were used alone. Leukothera(TM) is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.

Dr. Scott Kachlany, founder of Actinobac Biomed, explained. “Drug combination therapies for cancer are now frequently considered by oncologists due to their many advantages, which include the possibility of reducing doses of toxic chemotherapeutic agents and a lower chance of developing drug resistance,” he said. “The biological mechanism of Leukothera(TM) differs from that of other cancer drugs so including it to blood cancer treatment protocols may be a highly effective strategy.”

Actinobac Biomed, Inc. was founded in 2009 with financial backing from Foundation Venture Capital Group, LLC, to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey. The company has exclusively licensed the rights to develop Leukothera(TM )as a therapeutic agent for the treatment of hematologic malignancies, autoimmune and inflammatory diseases and HIV infection.

“We provided early seed funding to Actinobac because we are convinced that they are working on breakthrough research that can make a huge difference for people suffering with leukemia and other diseases,” said James M. Golubieski, president of Foundation Venture Capital Group (www.foundationventure.com), an affiliate of New Jersey Health Foundation.

For more information about Foundation Venture Capital Group, contact Jim Golubieski at (908) 731-6601 or jgolubieski@njhf.org.

For more information or to explore ways in which to partner with Actinobac, contact them at (732) 371-2694, info@actinobac.com or visit www.actinobac.com.

SOURCE Foundation Venture Capital Group, LLC


Source: newswire



comments powered by Disqus